--- title: "Thyreogen" canonical_url: https://bestpeptidecalculator.app/library/thyreogen description: "Peptide preparation derived from thyroid tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Thyreogen itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Thyreogen Thyreogen is a khavinson peptide bioregulator. The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Peptide preparation derived from thyroid tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Thyreogen itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators. Categories: Experimental. ## Classification - Type: Khavinson peptide bioregulator / research - Mechanism class: Short Peptide Bioregulator - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Claims specific to the thyroid preparation should be read as marketing rather than established pharmacology. ## Evidence - Evidence level: Insufficient Evidence - Highest documented: None documented - Human trials: 0 - Controlled human trials: 0 - Preclinical sources: 0 No human dose is established for this compound. Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. [Peptide bioregulator efficacy in the correction of reduced thyroid gland function in the residents of Magadan Region]. Adv Gerontol. 2005. 2005. Human study (early or uncontrolled). Population: Residents of the Magadan Region with reduced thyroid function (n not stated in the indexed abstract). Not reported in the indexed abstract, which describes only the background and the product. Research on a related compound, not this one. Limitations: Studied an analog, not Thyreogen itself [Source](https://pubmed.ncbi.nlm.nih.gov/16075681/) ## Safety Human safety basis: No controlled human safety data Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use.. ## Regulatory status Thyreogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - Availability: Research-Only ## Frequently asked questions ### What is Thyreogen? Peptide preparation derived from thyroid tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Thyreogen itself is indexed in PubMed, controlled or otherwise; the studies cited here are class-level work on short peptide bioregulators. ### How does Thyreogen work? The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. ### Is Thyreogen FDA approved? No. Thyreogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. ### What peptides are similar to Thyreogen? Compounds most often compared with Thyreogen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/) - [Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001](https://pubmed.ncbi.nlm.nih.gov/11713572/) - [Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/) - [Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002](https://pubmed.ncbi.nlm.nih.gov/12170291/) - [Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019](https://pubmed.ncbi.nlm.nih.gov/31099784/)